Compare Stocks: XFOR, IMTX, VOR, and MNKD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$7.59 -10.1%	$9.04	$7.40 ▼ $12.41	$1.15B	1.36	703,809 shs	1.26 million shs
MNKD MannKind	$3.80 -3.8%	$3.86	$2.23 ▼ $6.51	$1.27B	1.09	5.06 million shs	4.61 million shs
VOR Vor Biopharma	$18.69 +3.5%	$22.09	$6.50 ▼ $39.49	$1.07B	1.78	1.31 million shs	773,269 shs
XFOR X4 Pharmaceuticals	$2.83	$3.81	$2.74 ▼ $4.83	$280.59M	0.46	1.26 million shs	911,397 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	-3.87%	+1.32%	-10.50%	-15.18%	-6.22%
MNKD MannKind	+1.28%	+20.06%	-0.75%	-12.61%	-26.58%
VOR Vor Biopharma	-5.35%	-2.06%	-20.23%	-12.29%	-54.00%
XFOR X4 Pharmaceuticals	-2.41%	-5.67%	-30.47%	-31.48%	-21.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMTX Immatics	$7.59 -10.1%	$9.04	$7.40 ▼ $12.41	$1.15B	1.36	703,809 shs	1.26 million shs
MNKD MannKind	$3.80 -3.8%	$3.86	$2.23 ▼ $6.51	$1.27B	1.09	5.06 million shs	4.61 million shs
VOR Vor Biopharma	$18.69 +3.5%	$22.09	$6.50 ▼ $39.49	$1.07B	1.78	1.31 million shs	773,269 shs
XFOR X4 Pharmaceuticals	$2.83	$3.81	$2.74 ▼ $4.83	$280.59M	0.46	1.26 million shs	911,397 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMTX Immatics	-3.87%	+1.32%	-10.50%	-15.18%	-6.22%
MNKD MannKind	+1.28%	+20.06%	-0.75%	-12.61%	-26.58%
VOR Vor Biopharma	-5.35%	-2.06%	-20.23%	-12.29%	-54.00%
XFOR X4 Pharmaceuticals	-2.41%	-5.67%	-30.47%	-31.48%	-21.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMTX Immatics	2.63	Moderate Buy	$20.60	171.41% Upside
MNKD MannKind	2.50	Moderate Buy	$8.34	119.57% Upside
VOR Vor Biopharma	2.90	Moderate Buy	$41.71	123.19% Upside
XFOR X4 Pharmaceuticals	2.50	Moderate Buy	$11.25	297.53% Upside

Current Analyst Ratings Breakdown

Latest XFOR, IMTX, VOR, and MNKD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	IMTX Immatics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/16/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
9/11/2026	MNKD MannKind	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$8.00
9/3/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/25/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/25/2026	IMTX Immatics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$17.00
8/12/2026	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $27.00
8/11/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D+)
8/11/2026	XFOR X4 Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	MNKD MannKind	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$14.00 ➝ $13.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMTX Immatics	$54.60M	19.00	N/A	N/A	$4.09 per share	1.86
MNKD MannKind	$348.97M	3.50	$0.06 per share	63.83	($0.17) per share	-22.35
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	$35.11M	7.99	N/A	N/A	$2.13 per share	1.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.13	N/A	N/A	N/A	-11.08%	N/A	-6.31%	11/4/2026 (Estimated)
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	-$79.20M	-$1.20	N/A	N/A	N/A	-568.80%	-63.05%	-36.89%	11/4/2026 (Estimated)

Latest XFOR, IMTX, VOR, and MNKD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/11/2026	Q2 2026	VOR Vor Biopharma	-$0.69	-$0.80	-$0.11	-$1.16	N/A	N/A
8/6/2026	Q2 2026	XFOR X4 Pharmaceuticals	-$0.1760	-$0.13	+$0.0460	-$0.13	$2.42 million	$8.81 million
8/5/2026	Q2 2026	MNKD MannKind	-$0.0075	-$0.01	-$0.0025	-$0.06	$108.08 million	$109.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMTX Immatics	N/A	7.54	7.54
MNKD MannKind	N/A	1.72	1.41
VOR Vor Biopharma	N/A	N/A	N/A
XFOR X4 Pharmaceuticals	0.49	11.30	11.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMTX Immatics	64.41%
MNKD MannKind	49.55%
VOR Vor Biopharma	97.29%
XFOR X4 Pharmaceuticals	72.03%

Insider Ownership

Company	Insider Ownership
IMTX Immatics	3.30%
MNKD MannKind	2.60%
VOR Vor Biopharma	0.27%
XFOR X4 Pharmaceuticals	1.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMTX Immatics	704	136.69 million	132.18 million	Optionable
MNKD MannKind	592	321.54 million	313.18 million	Optionable
VOR Vor Biopharma	76	59.16 million	59.00 million	N/A
XFOR X4 Pharmaceuticals	45	99.15 million	98.03 million	No Data

XFOR, IMTX, VOR, and MNKD Headlines

Recent News About These Companies

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1 at 4:30 PM | globenewswire.com

X4 Pharmaceuticals stock gets a smaller Phase 3 trial

September 29 at 12:57 PM | ad-hoc-news.deA

X4 Pharmaceuticals, Inc. (XFOR)

September 26, 2026 | finance.yahoo.com

Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround

September 24, 2026 | zacks.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $11.25 Consensus Price Target from Brokerages

September 16, 2026 | defenseworld.netD

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Rating of "Moderate Buy" from Analysts

September 13, 2026 | marketbeat.com

X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

September 11, 2026 | zacks.com

XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets

September 11, 2026 | marketbeat.com

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

September 9, 2026 | globenewswire.com

X4 Pharmaceuticals Announces Positive Outcome From FDA Type C Meeting And Provides Update On 4WARD Phase 3 Chronic Neutropenia Trial

September 8, 2026 | marketscreener.comM

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

September 8, 2026 | globenewswire.com

Braidwell LP Sells 350,200 Shares of X4 Pharmaceuticals, Inc. $XFOR

September 3, 2026 | marketbeat.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026 | globenewswire.com

X4 Pharmaceuticals (NASDAQ:XFOR) President Sells $109,117.44 in Stock

August 14, 2026 | insidertrades.com

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

August 11, 2026 | zacks.com

X4 Pharmaceuticals (XFOR) Receives a Buy from Stifel Nicolaus

August 9, 2026 | theglobeandmail.com

X4 Pharmaceuticals: Q2 Earnings Snapshot

August 6, 2026 | chron.com

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026 | markets.businessinsider.com

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

X4 Pharmaceuticals, Inc. Common Stock (XFOR) After Hours Quote

July 13, 2026 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XFOR, IMTX, VOR, and MNKD Company Descriptions

Immatics NASDAQ:IMTX

$7.59 -0.85 (-10.07%)

Closing price 04:00 PM Eastern

Extended Trading

$7.59 0.00 (0.00%)

As of 07:30 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

MannKind NASDAQ:MNKD

$3.80 -0.15 (-3.80%)

Closing price 04:00 PM Eastern

Extended Trading

$3.80 0.00 (0.00%)

As of 07:30 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Vor Biopharma NASDAQ:VOR

$18.69 +0.63 (+3.49%)

Closing price 04:00 PM Eastern

Extended Trading

$18.77 +0.08 (+0.45%)

As of 07:30 PM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

X4 Pharmaceuticals NASDAQ:XFOR

$2.83 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.84 +0.01 (+0.21%)

As of 07:55 PM Eastern

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XFOR, IMTX, VOR, and MNKD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XFOR, IMTX, VOR, and MNKD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XFOR, IMTX, VOR, and MNKD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XFOR, IMTX, VOR, and MNKD Company Descriptions

Immatics NASDAQ:IMTX

MannKind NASDAQ:MNKD

Vor Biopharma NASDAQ:VOR

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XFOR, IMTX, VOR, and MNKD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XFOR, IMTX, VOR, and MNKD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XFOR, IMTX, VOR, and MNKD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XFOR, IMTX, VOR, and MNKD Company Descriptions

Immatics NASDAQ:IMTX

MannKind NASDAQ:MNKD

Vor Biopharma NASDAQ:VOR

X4 Pharmaceuticals NASDAQ:XFOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools